• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aspire Biopharma Holdings, Inc. - Common Stock (NQ:ASBP)

0.3302 -0.0064 (-1.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
October 06, 2025
Via ACCESS Newswire
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
October 03, 2025
Via ACCESS Newswire
TOMI Environmental (NASDAQ: TOMZ) Expands SteraMist – Protecting People from Germs, Viruses & Biohazards | More Stocks Inside
October 01, 2025
Via AB Newswire
Topics Artificial Intelligence
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
October 01, 2025
Via ACCESS Newswire
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
September 17, 2025
Via ACCESS Newswire
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement
September 16, 2025
Via ACCESS Newswire
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
September 03, 2025
Via ACCESS Newswire
Sidoti Events, LLC's Virtual August Micro-Cap Conference
August 19, 2025
Via ACCESS Newswire
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
August 18, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20
August 14, 2025
Via ACCESS Newswire
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
August 13, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement
July 31, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc. Announces CEO Transition
July 30, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
July 22, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement
July 09, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
June 24, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
June 10, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
May 28, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
May 20, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
May 08, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
April 29, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
April 14, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
April 11, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
April 09, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
March 20, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
March 13, 2025
Via ACCESS Newswire
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
March 11, 2025
New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company")... 
Via Newsfile
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
March 03, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
February 25, 2025
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
February 20, 2025
Via ACCESS Newswire
Recent Quotes
View More
Symbol Price Change (%)
GOOG  237.49
-4.72 (-1.95%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap